FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)
出版年份 2013 全文链接
标题
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume 24, Issue 8, Pages 2062-2067
出版商
Oxford University Press (OUP)
发表日期
2013-05-11
DOI
10.1093/annonc/mdt165
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first line metastatic colorectal cancer (mCRC).
- (2017) J. Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial.
- (2017) Fotios Loupakis et al. JOURNAL OF CLINICAL ONCOLOGY
- A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial
- (2012) Z Saridaki et al. BRITISH JOURNAL OF CANCER
- Emerging VEGF-receptor inhibitors for colorectal cancer
- (2012) Erika Martinelli et al. EXPERT OPINION ON EMERGING DRUGS
- Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis
- (2011) Claire L. Vale et al. CANCER TREATMENT REVIEWS
- Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer
- (2011) F. Molinari et al. CLINICAL CANCER RESEARCH
- Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial
- (2011) E. Assenat et al. ONCOLOGIST
- Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial
- (2010) C Garufi et al. BRITISH JOURNAL OF CANCER
- Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis
- (2010) G. Masi et al. JNCI-Journal of the National Cancer Institute
- Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
- (2010) Gianluca Masi et al. LANCET ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
- (2009) F Loupakis et al. BRITISH JOURNAL OF CANCER
- Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy
- (2009) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now